Division of Angiology, Heart and Vessel Department, Lausanne University Hospital, Lausanne, Switzerland.
Curr Vasc Pharmacol. 2020;18(3):237-248. doi: 10.2174/1570161117666190212112743.
Bleeding represents the most important complication of antithrombotic treatment, including anticoagulant and antiplatelet therapies. A number of scores were proposed to evaluate the risk of bleeding both for anticoagulant and antiplatelet treatment. In the last decade, 5 bleeding risk scores were published for use in atrial fibrillation patients, and 3 scores for patients receiving anticoagulants for venous thromboembolism therapy or prophylaxis. In addition, 3 scores were recently developed to assess inhospital or short-term bleeding risk in patients receiving antiplatelet therapy after Acute Coronary Syndrome (ACS) and Percutaneous Coronary Intervention (PCI). Furthermore, 3 additional scores have focused on long-term bleeding in outpatients receiving dual antiplatelet therapy after PCI. The aim of this review is to consider the evidence on bleeding scores.
出血是抗栓治疗（包括抗凝和抗血小板治疗）最重要的并发症。已经提出了许多评分来评估抗凝和抗血小板治疗的出血风险。在过去的十年中，已经发表了 5 个用于房颤患者的出血风险评分，以及 3 个用于接受抗凝治疗预防或治疗静脉血栓栓塞症的患者的评分。此外，最近还开发了 3 个评分来评估急性冠状动脉综合征（ACS）和经皮冠状动脉介入治疗（PCI）后接受抗血小板治疗的患者的住院或短期出血风险。此外，还有 3 个额外的评分关注的是 PCI 后接受双联抗血小板治疗的门诊患者的长期出血风险。本综述的目的是考虑关于出血评分的证据。
